Esaxerenone
Esaxerenone Basic information
- Product Name:
- Esaxerenone
- Synonyms:
-
- cs3150
- cs-3150
- Esaxerenone
- CS-3150 (Esaxerenone
- XL-550)
- CS-2614
- 5G,100G,500G
- CS-3150; CS 3150; CS3150; XL-550; XL550; XL 550.
- CAS:
- 1632006-28-0
- MF:
- C22H21F3N2O4S
- MW:
- 466.48
- Mol File:
- 1632006-28-0.mol
Esaxerenone Chemical Properties
- Boiling point:
- 581.3±50.0 °C(Predicted)
- Density
- 1.35±0.1 g/cm3(Predicted)
- solubility
- DMSO:100.0(Max Conc. mg/mL);214.37(Max Conc. mM)
- pka
- 12.76±0.70(Predicted)
- form
- Solid
- color
- White to light yellow
- InChI
- InChI=1S/C22H21F3N2O4S/c1-14-18(21(29)26-15-7-9-16(10-8-15)32(2,30)31)13-27(11-12-28)20(14)17-5-3-4-6-19(17)22(23,24)25/h3-10,13,28H,11-12H2,1-2H3,(H,26,29)
- InChIKey
- NOSNHVJANRODGR-UHFFFAOYSA-N
- SMILES
- C(N1C=C(C(=O)NC2C=CC(S(=O)(=O)C)=CC=2)C(C)=C1C1C=CC=CC=1C(F)(F)F)CO
Esaxerenone Usage And Synthesis
Uses
Esaxerenone, is a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Biological Activity
Esaxerenone exerts its antihypertensive effect by blocking excessive activation of the mineralocorticoid receptor by endogenous ligands (such as aldosterone), has a mineralocorticoid receptor selectivity at least 1000-fold greater than other steroid hormone receptors, a long half-life, high oral bioavailability, and has a more significant antihypertensive effect than spironolactone or eplerenone.
Synthesis
below shows the synthesis route of Esaxerenone
in vivo
After single oral administration of Esaxerenone at 0.1, 0.3, 1, and 3?mg/kg, maximum plasma concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) are increased with dose. Time to reach the maximum plasma concentration (Tmax) of Esaxerenone ranges from 2.0 to 4.5?h. After intravenous administration of Esaxerenone at 0.1, 0.3, 1, and 3?mg/kg, the total body clearance (CL) and distribution volume at steady state (Vss) are 3.53 to 6.69?mL/min/kg and 1.47 to 2.49?L/kg, respectively, in rats, and 2.79 to 3.69?mL/min/kg and 1.34 to 1.54?L/kg, respectively, in cynomolgus monkeys. Up to 168?h after administration, 3.9% and 91.4% of dosed radioactivity are excreted in rat urine and feces, respectively, and 95.2% in total. In monkeys, the excreted radioactivity up to 168?h is 11.5% in urine, 82.3% in feces, and 93.9% in total[1].
EsaxerenoneSupplier
- Tel
- 025-58741518 13327700685
- sales@vcarepharmatech.com
- Tel
- 17702719238 18971495150;
- sales@sun-shinechem.com
- Tel
- 021-02136680027 15800370750
- 1706640024@qq.com
- Tel
- 0523-86818997 18652728585
- sales@allyrise.com
- Tel
- 021-52996696,15000506266 15000506266